Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New fingerstick test for blood thinner monitoring put to the test

NCT ID NCT03682419

First seen Jun 17, 2026 · Last updated Jun 20, 2026 · Updated 1 time

Summary

This study tested how well a small, portable device (LumiraDx) measures blood clotting (INR) compared to standard lab tests. Researchers collected blood from 420 adults, some taking warfarin and some not, using both a fingerstick and a vein draw. The goal was to see if the device is accurate enough for use in clinics, potentially making it easier to monitor patients on blood thinners.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Glasgow Royal Infirmary Clinical Research Facility

    Glasgow, G4 0SF, United Kingdom

  • Golden Jubilee National Hospital

    Glasgow, G81 4DY, United Kingdom

  • Wishaw General Hospital, NHS Lanarkshire

    Wishaw, ML2 0DP, United Kingdom

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could provide a faster, easier way to monitor blood clotting in clinics, helping manage medications like warfarin more conveniently.

What could go wrong

This is a completed device accuracy study, not a treatment trial. It does not test any new therapy or health outcome, so its impact is limited to improving monitoring, not curing disease.

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome atrial fibrillation Donath-Landsteiner hemolytic anemia Dressler syndrome pulmonary embolism thrombophilia venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.